B of A Securities: Downgrading Ionic Pharmaceuticals Inc(IONS. US) rating, adjusted from Buy to below the broader market rating, with a target price adjusted from $40.00 to $30.00.
Ionis Pharmaceuticals (IONS.US) Company Profile: Ionic Pharmaceuticals uses antisense technology to develop and commercialize human therapeutic drugs. It operates through Ionis Core and Akcea Therapeutics. The Ionis Core division leverages a new drug discovery platform to generate drug pipelines. Al-Aqsa Therapeutics develops and markets drugs for the treatment of cardiometabolic diseases. The company is founded by Stanley M. T. Crook, David M. J. Echol, Christopher M. K. Mirabelle and Brett P. Monia was founded in 1989 and is headquartered in Carlsbad, California.
The above content is compiled by Securities Star based on public information, if you have any questions, please contact us.